{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:03:20Z","timestamp":1777878200854,"version":"3.51.4"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Amgen, Inc."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Most multiple myeloma (MM) patients ultimately progress, with remission duration decreasing after first relapse. Recently, novel agents have been approved for the treatment of relapsed MM. There is a paucity of real-world data on these treatments. We sought to compare time to next treatment (TTNT) in MM patients in their second line of therapy (LOT2), treated with common proteasome inhibitor (PI)-based triplets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Adult MM patients who received carfilzomib (K) between 1 November 2013 and 29 February 2016 at US Oncology Network (USON) clinics utilizing iKnowMed\u2122 electronic health records (EHRs) were identified. Patients were included if they were \u2a7e18\u2009years of age, not enrolled in clinical trials, had \u2a7e2 visits at a USON clinic and received LOT2 regimens consisting of: K+lenalidomide with steroid (KRd), bortezomib+lenalidomide with steroid (VRd), or bortezomib+cyclophosphamide with steroid (VCyd). TTNT was estimated from LOT2 initiation to LOT3 initiation using the Kaplan\u2013Meier method, and hazard ratios (HRs) were estimated using Cox modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 718 patients received a K-containing regimen sometime during their MM treatment (LOT1 to LOT5). Of these, 156 patients received: KRd ( n = 112; 71.8%), VRd ( n =27; 17.3%), or VCyd ( n = 17; 10.9%). Baseline characteristics were similar between groups (mean age: 64.8\u2009years; 58% male). Median TTNT was longest for KRd [25.3\u2009months; 95% confidence interval (CI): 19.71\u2013NR], versus VRd or VCyd (VRd median TTNT: 10.2\u2009months, 95% CI: 4.24\u201312.71; VCyd: 6.5\u2009months, 95% CI: 3.02\u201312.78; log-rank p &lt; 0.0001). The adjusted HR for KRd was 0.19 (95% CI: 0.11\u20130.37), compared with VRd.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Considering the real-world nature of these data, the median TTNT observed with KRd was relatively consistent, with progression-free survival (PFS) for KRd observed in the phase III ASPIRE trial (median PFS: ITT population = 26.3\u2009months; LOT2 = 29.6\u2009months). Patients who received KRd at first relapse had significantly longer TTNT, compared with those on VRd or VCyd, confirming the value of KRd as an important treatment option for relapsed MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2040620718816699","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T08:28:57Z","timestamp":1547195337000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":16,"title":["A real-world comparative analysis of carfilzomib and other systemic multiple myeloma chemotherapies in a US community oncology setting"],"prefix":"10.1177","volume":"10","author":[{"given":"Robert M.","family":"Rifkin","sequence":"first","affiliation":[{"name":"Rocky Mountain Cancer Centers, Denver, CO, USA McKesson Specialty Health, The US Oncology Network, The Woodlands, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. Susan","family":"Amirian","sequence":"additional","affiliation":[{"name":"McKesson Specialty Health, The US Oncology Network, The Woodlands, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2467-8663","authenticated-orcid":false,"given":"Kathleen M.","family":"Aguilar","sequence":"additional","affiliation":[{"name":"McKesson Specialty Health, The US Oncology Network, The Woodlands, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wilson","sequence":"additional","affiliation":[{"name":"McKesson Specialty Health, The US Oncology Network, The Woodlands, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marley","family":"Boyd","sequence":"additional","affiliation":[{"name":"McKesson Specialty Health, The US Oncology Network, The Woodlands, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Mezzi","sequence":"additional","affiliation":[{"name":"Amgen, Inc., Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Amgen, Inc., 1120 Veterans Blvd, South San Francisco, CA 91320, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,1,11]]},"reference":[{"key":"bibr1-2040620718816699","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"bibr2-2040620718816699","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: multiple myeloma. Version 4.2018, https:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf (2018, accessed 13 March 2018)."},{"key":"bibr3-2040620718816699","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.129189"},{"key":"bibr4-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"bibr5-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1361035"},{"key":"bibr6-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2015.1105202"},{"key":"bibr7-2040620718816699","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S102328"},{"key":"bibr8-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"bibr9-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"bibr10-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2017.01.003"},{"key":"bibr11-2040620718816699","first-page":"236","volume":"23","author":"Chen CC","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr12-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8"},{"key":"bibr13-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0433"},{"key":"bibr14-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-120030218"},{"key":"bibr15-2040620718816699","first-page":"4996","volume":"62","author":"LeBlanc R","year":"2002","journal-title":"Cancer Res"},{"key":"bibr16-2040620718816699","unstructured":"Kyprolis\u00ae (carfilzomib). Prescribing information, http:\/\/pi.amgen.com\/united_states\/kyprolis\/kyprolis_pi.pdf (accessed 23 May 2016)."},{"key":"bibr17-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8"},{"key":"bibr18-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"bibr19-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"bibr20-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.06.016"},{"key":"bibr21-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.12.012"},{"key":"bibr22-2040620718816699","unstructured":"Federal Register. Section 203 of the Bipartisan Budget Agreement: restriction on access to the death master file. United States Statutes at Large, 2013, pp. 1177\u20131179."},{"key":"bibr23-2040620718816699","volume-title":"Presented at the American Society of Hematology 59th Annual Meeting","author":"Chari A","year":"2017"},{"key":"bibr24-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5032"},{"key":"bibr25-2040620718816699","doi-asserted-by":"publisher","DOI":"10.1016\/j.apnr.2010.02.004"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620718816699","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620718816699","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620718816699","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:14:21Z","timestamp":1777590861000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620718816699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":25,"alternative-id":["10.1177\/2040620718816699"],"URL":"https:\/\/doi.org\/10.1177\/2040620718816699","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]},"article-number":"2040620718816699"}}